共 85 条
- [1] Siegel RL(2016)Cancer statistics, 2016 CA Cancer J Clin 66 7-30
- [2] Miller KD(2014)Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer BJU Int 114 E25-E31
- [3] Jemal A(2011)Characterising the castration-resistant prostate cancer population: a systematic review Int J Clin Pract 65 1180-1192
- [4] Sonpavde G(2008)New drug development in metastatic prostate cancer Urol Oncol 26 430-437
- [5] Pond GR(2017)Duration of treatment in prostate cancer patients treated with abiraterone acetate or enzalutamide J Manag Care Spec Pharm 23 225-235
- [6] Armstrong AJ(2016)Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: a literature based meta-analysis of randomized trials Eur J Cancer 61 111-121
- [7] Kirby M(2015)U.S. Food and Drug Administration Approval Summary: enzalutamide for the treatment of patients with chemotherapy-naive metastatic castration-resistant prostate cancer Oncologist 20 960-966
- [8] Hirst C(2016)Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer BJU Int 117 215-225
- [9] Crawford ED(2017)Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study Eur Urol 71 151-154
- [10] Armstrong AJ(2015)Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study Lancet Oncol 16 152-160